Implantable Medical Device Batteries Market Global Report 2026

The implantable medical device batteries market size has grown strongly in recent years. It will grow from $1.12 billion in 2025 to $1.21 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to increasing adoption of implantable medical devices, rising demand for long-lasting power sources for medical devices, growing utilization of cardiac rhythm management devices, increasing demand for dependable battery performance, and rising emphasis on implantable device safety.

The implantable medical device batteries market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. Growth during the forecast period is likely to be driven by increasing adoption of advanced neurostimulation devices, rising demand for smaller implantable medical devices, growing development of rechargeable implantable batteries, increasing demand for higher energy density, and greater adoption of next-generation implantable drug delivery systems. Key trends during the forecast period include increasing development of high-energy-density implantable batteries, greater adoption of long-life primary battery technologies, rising development of miniaturized implantable power sources, increasing focus on hermetically sealed battery designs, and growing demand for predictable and stable battery discharge.

The increasing prevalence of cardiovascular and neurological disorders is expected to drive the growth of the implantable medical device batteries market going forward. Cardiovascular and neurological disorders refer to chronic conditions affecting the heart, blood vessels, brain, spinal cord, and nervous system, which often require long-term treatment using implantable medical devices such as pacemakers, implantable cardioverter defibrillators, deep brain stimulators, and neurostimulators. The rising prevalence of cardiovascular and neurological disorders is associated with an aging global population, which increases the likelihood of chronic cardiovascular and neurological conditions among older adults. Implantable medical device batteries support the management of cardiovascular and neurological disorders by supplying reliable and long-lasting power to implanted devices. They enable the continuous functioning of devices such as pacemakers, implantable cardioverter defibrillators, and neurostimulators, contributing to treatment effectiveness and improved patient outcomes. For instance, in August 2025, according to the National Institutes of Health (NIH), a US-based federal government agency, cardiovascular prevalence is projected to increase by 90.0% from 2025 to 2050, with cardiovascular deaths rising from 20.5 million in 2025 to 35.6 million in 2050. Therefore, the increasing prevalence of cardiovascular and neurological disorders is driving the growth of the implantable medical device batteries market.

Major companies operating in the implantable medical device batteries market are focusing on developing advanced medical battery solutions, such as high-pulse medical-grade batteries, to improve power reliability, operating life, and performance in critical medical devices. High-pulse medical-grade batteries are specialized batteries engineered to provide stable, high-rate power pulses while maintaining dependable performance under demanding environmental conditions and meeting the power requirements of medical devices. For instance, in April 2026, EVE Energy Co. Ltd., a China-based battery manufacturer, unveiled the CR123AP medical-grade battery at the China International Medical Equipment Fair (CMEF) Spring Edition. Developed as an advanced medical battery solution, the CR123AP incorporates high-pulse output technology, extended cycle life, strong rate capability, and improved low-temperature performance, delivering pulse output capability up to 5.92 times that of competing products at -20°C. The battery also employs a dry electrode manufacturing process to lower carbon emissions while enhancing electrode conductivity and mechanical stability, enabling dependable power delivery across critical medical equipment and contributing to the wider medical battery ecosystem serving implantable devices.

In January 2026, Ilika plc, a UK-based solid-state battery technology company, partnered with Cirtec Medical LLC to manufacture batteries for active implantable medical devices. Through this partnership, the companies aim to accelerate the commercialization and integration of Ilika’s Stereax miniature solid-state batteries into next-generation implantable medical devices by combining Ilika’s expertise in battery technology with Cirtec Medical’s medical device design, engineering, and manufacturing capabilities. Cirtec Medical LLC is a US-based medical device development and manufacturing company that provides implantable medical device solutions, including manufacturing support for miniature solid-state batteries used in implantable applications.

Major companies operating in the implantable medical device batteries market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, LivaNova PLC, Inspire Medical Systems Inc., Cochlear Limited, Mainstay Medical Holdings plc, EnerSys, Resonetics LLC, EVE Energy Co. Ltd., Maxell Ltd., Wyon AG, Ilika plc, Ensurge Micropower ASA, Cymbet Corporation, Excellatron Solid State LLC, InjectPower S.r.l., Integer Holdings Corporation.

North America was the dominating region in the implantable medical device batteries market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the implantable medical device batteries market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the implantable medical device batteries market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The implantable medical device batteries consists of sales of implantable lithium-ion batteries, lithium-iodine batteries, lithium silver vanadium oxide batteries, lithium carbon monofluoride batteries, rechargeable implantable batteries, and primary implantable batteries. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

This product will be delivered within 3-5 business days.